//
uglas L. Arnold
Ludwig Kappos
Patrick Vermersch
Ralf Gold
Amit Bar-Or
Gavin Giovannoni
Bruce A.C. Cree
Daniela Piani Meier
Shannon Ritter
Goeril Karlsson
Frank Dahlke
Thomas Hach
Robert J. Fox
Brain Imaging Centre, Montreal Neurological Institute and Hospital, McGill University, Montreal, QC, Canada
NeuroRx Research, Montreal, QC, Canada
Neurologic Clinic and Policlinic and Research Center for Clinical Neuroimmunology and Neuroscience, Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland
Univ. Lille, Inserm UMR U1172 LilNCog, CHU Lille, FHU Imminent, Lille, France
Department for Neurology, St. Josef-Hospital, Ruhr University, Bochum, Germany
Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
Blizard Institute, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, London, UK
Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA, USA San Francisco CA United States
Novartis AG, Basel, Switzerland
Novartis Pharmaceutical Corporation, East Hanover, NJ
Mellen Center for Treatment and Research in Multiple Sclerosis, Neurological Institute, Cleveland, OH, USA
Canada
Switzerland
France
Germany
United States
United Kingdom
Novartis AG
N/A
N/A
N/A
Siponimod
N/A
Randomized
Placebo Control
Open Label
III
N/A
N/A
N/A